Q-omics provides the consensus-scored SCN4B profile across patient tissues and cancer cell-line models. SCN4B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SCN4B is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, SCN4B RNA expression shows 19,127 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, BLCA, and LUAD as cancer lineages where SCN4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCN4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCN4B survival associations across molecular data types. SCN4B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCN4B RNA expression–survival associations across cancer types. High SCN4B expression shows unfavorable associations in UVM, BLCA and OV, but favorable associations in KIRC, LUAD and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SCN4B RNA expression.
This table summarizes SCN4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SCN4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCN4B shows lower tumor expression in BLCA, COAD, LUAD and THCA and higher tumor expression in KIRC and LIHC. The BLCA box plot shows higher SCN4B RNA expression in normal versus tumor tissue (log2 FC = −2.313, t-test p < 0.001).
This table shows molecular features associated with SCN4B in patient tissues and cancer cell lines. In patient samples, SCN4B shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SCN4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
